<DOC>
	<DOCNO>NCT01041755</DOCNO>
	<brief_summary>Hepatic encephalopathy cause effect brain substance normal circumstance efficiently metabolize liver . The hyperammonemia main factor responsible development hepatic encephalopathy . In patient cirrhosis , reduction hepatocellular function generation portosystemic shunt contribute increase serum ammonium . The current therapeutic approach , aim reduce blood ammonium level . Administration non-absorbable disaccharide , become standard treatment hepatic encephalopathy.There adequate clinical trial compare efficacy L-Ornithine-L-Aspartate ( LOLA ) infusion lactose enemas treatment acute hepatic encephalopathy .</brief_summary>
	<brief_title>Efficacy L-Ornithine L-Aspartate Acute Hepatic Encephalopathy .</brief_title>
	<detailed_description>The main impact hepatic encephalopathy patient cirrhosis related cost , association decrease survival quality life therefore clearly establish effectiveness therapeutic intervention use disorder . At end nineteenth century ammonium identify main agent responsible development syndrome hepatic encephalopathy . Since , reduce nitrogen compound intestine consider main therapeutic measure . On conceptual base , nonabsorbable disaccharide first line therapy hepatic encephalopathy . Current knowledge indicate organ muscle , brain kidney involve generation ammonium , set pace development new treatment , able act systemically metabolism elimination ammonia . L-ornithine L-aspartate ( LOLA ) lower ammonium concentration animal human model hyperammonemia . There adequate clinical trial compare efficacy LOLA infusion lactose enemas treatment acute hepatic encephalopathy .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<criteria>Patients cirrhosis etiology , diagnose ultrasound , clinical / histologic criterion Patients 18 year 75 Patients hepatic encephalopathy grade 34 accord criterion West Haven Patients hyperammonemia &gt; 35 Âµmol/l Evidence neurological psychiatric abnormality Renal failure ( serum creatinine great 3 mg / dL ) Use drug affect central nervous system Withdrawal Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Encephalopathy</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>